

Accordingly, as all of the claims in groups VII-XII are directed to employing the same method to inhibit the recited diseases, a soluble polypeptide, and all of the claims in groups VII-XII share a common mechanism through which the various diseases are inhibited, a p30 polypeptide, there is no added burden to search the claims of groups VIII-XII with group VII in the subject application. That there is no added burden to search the groups VII-XII claims together in the application is further evidenced by the fact that all of the groups are classified in Class 424, subclass 184.1. In sum, as there is no undue burden on the Examiner to search the claims of groups VII-XII together in the application, Applicant respectfully requests rejoinder of the groups VIII-XII claims with the elected group VII claims for examination in the application.

Regarding the Sequence Listing


Applicants submit herewith substitute paper and computer readable copies of the Sequence Listing in accordance with 37 C.F.R. §§1.821(c) and (e)-1.825. The substitute copies of the Sequence Listing are identical. The substitute copies of the Sequence Listing do not add new matter. A statement under 37 C.F.R. §§1.821(f) and (g) to this effect is submitted concurrently herewith. Accordingly, as no new matter has been added, entry of the substitute paper and computer readable copies of the Sequence Listing is respectfully requested.

CONCLUSION

If the Examiner would like to discuss any of the issues raised in the Action, Applicant's representative can be reached at (858) 509-4065. Please charge any additional fees, or make any credits, to Deposit Account No. 03-3975.

Respectfully submitted,

Date: 1-25-02


Robert M. Bedgood, Ph.D.
Reg. No. 43,488
Agent for Applicant

Pillsbury Winthrop LLP
50 Fremont Street
P.O. Box 7880
San Francisco, CA 94105
Telephone: (858) 509-4065
Facsimile: (858) 509-4010